Finance

Lists
RLMD:NASDAQ
Relmada Therapeutics Inc
$3.62
-1.17%
(-0.043) 1D
$3.60
-0.47% (-0.017)
After hours
Closed: Oct 2, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RLMD...
Open
$3.72
High
$3.73
Low
$3.60
Mkt. cap
384.01M
Avg. vol.
1.17M
Volume
1.21M
52-wk high
$8.00
52-wk low
$1.80
EPS
-$0.96
Beta
0.51
Shares outstanding
106.67M
No. of employees
17
Open
$3.72
High
$3.73
Low
$3.60
Mkt. cap
384.01M
Avg. vol.
1.17M
Volume
1.21M
52-wk high
$8.00
52-wk low
$1.80
EPS
-$0.96
Beta
0.51
Shares outstanding
106.67M
No. of employees
17
News stories
From web sources and news partners
marketscreener.com
marketscreener.com
·
22 minutes ago
S&P maintains Romania at 'BBB-/A-3'
TradingView
TradingView
·
22 minutes ago
S&P 500 ends week lower despite Friday rally
bloomingbit
bloomingbit
·
29 minutes ago
U.S. Stocks Close Higher; Nasdaq Gains 1.19%
Invezz
Invezz
·
6 minutes ago
Dow rises 260 points as weak jobs data lifts US stocks
About Relmada Therapeutics Inc
CEO-
Employees17
Founded2004
HeadquartersCoral Gables, Florida, United States
SectorPharmaceutical industry
Websiterelmada.com
Analyst ratings
Based on 2 analysts giving stock ratings to RLMD in the past 3 months
Buy
Buy
2
Hold
0
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for RLMD in the last 3 months.
Highest
Current $3.62
$12.00 (+231.77%)
Average
$12.00 (+231.77%)
Lowest
$12.00 (+231.77%)
Analyst
Recommendation
Action
Price target
Projected
Date
Uy Ear
Mizuho Securities
Buy
Reiterated
$19.00
+425.3%
08/11/2026
Andres Y. Maldonado
H.C. Wainwright
Buy
Reiterated
$12.00
+231.8%
08/10/2026
Kelsey Goodwin
Piper Sandler
Buy
Maintained
$12.00
+231.8%
08/07/2026
Christopher Liu
Lucid Capital
Buy
Initiated
$14.00
+287.1%
03/02/2026
Last report
Nov 10, 2022
Fiscal period
Q3 2022
EPS / Est. (USD)
-$1.26 / -$1.47
+14.22%beat
Revenue / Est. (USD)
- / 0.00
Fiscal Q3 2022 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
4.04M
5.17M
8.09M
8.39M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6.29M
12.26M
11.37M
6.62M
Operating expense
10.33M
17.43M
19.46M
15.01M
Total operating expenses
10.33M
17.43M
19.46M
15.01M
Operating income
-10.33M
-17.43M
-19.46M
-15.01M
Other non operating income
-
-
-
-
EBT including unusual items
-10.09M
-19.87M
-19.05M
-12.91M
EBT excluding unusual items
-10.08M
-17.05M
-18.50M
-12.71M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-10.09M
-19.87M
-19.05M
-12.91M
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
247.01K
387.23K
959.76K
2.30M
Interest expense
-
-
-
-
Net interest expenses
247.01K
387.23K
959.76K
2.30M
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps